Holen Sie sich die Stockscreener-App
17.40
0.10%
-0.0192
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$17.42
Offen:
$17.52
24-Stunden-Volumen:
2.18M
Relative Volume:
0.24
Marktkapitalisierung:
$19.99B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-67.18
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
+2.67%
1M Leistung:
+4.09%
6M Leistung:
+28.91%
1J Leistung:
+83.38%
1-Tages-Spanne:
$17.37
$17.59
1-Wochen-Bereich:
$16.86
$17.59
52-Wochen-Spanne:
$9.465
$18.39
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.40 | 20.01B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
18.80 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.98 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.16 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.77 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
475.93 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - marketscreener.com
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com UK
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - Yahoo Finance
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan
ETFs Investing in Viatris, Inc. Stocks - TradingView
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Harrow adds TYRVAYA's global rights to dry eye portfolio - Glance by Eyes On Eyecare
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):